Hospital Victoria Eugenia De La Cruz Roja Espanola
- Address
- lock Available on a paid plan
Neurology Research in Alzheimer’s Disease
At Hospital Victoria Eugenia De La Cruz Roja Espanola in Sevilla, most of the neurology studies focus on Alzheimer’s disease and related nervous system diseases. The trials are exploring new ways to slow cognitive decline, support memory and daily function, and improve overall disease management in people at different stages of the condition.
- Testing new therapies for early Alzheimer’s disease and early symptomatic Alzheimer’s disease
- Evaluating treatments for mild to moderate Alzheimer’s disease and mild cognitive impairment linked to AD
- Assessing whether investigational approaches can slow cognitive and functional decline
Several studies also look at long-term safety and tolerability, helping determine whether these approaches may offer lasting benefit for patients living with Alzheimer’s-related conditions.
Mental Disorders and Behavioral Symptoms in Neurodegenerative Disease
This site also contributes to research in psychiatry and psychology, with a strong emphasis on mental disorders that appear alongside Alzheimer’s disease. The trials are designed to better understand and treat symptoms such as psychosis and agitation, aiming to improve comfort, behavior, and quality of life for patients and caregivers.
- Studying treatments for psychosis associated with Alzheimer’s disease
- Evaluating options for agitation associated with Alzheimer’s disease
- Exploring whether new therapies can reduce hallucinations, delusions, and disruptive behaviors
These studies reflect a broader effort to address the neuropsychiatric aspects of dementia, not only the memory-related symptoms.
Parkinson’s Disease and Motivation-Related Symptoms
Research at this hospital also includes Parkinson’s disease, with attention to apathy, a symptom that can significantly affect day-to-day functioning. The goal is to assess whether new therapies can help improve motivation and engagement while remaining safe and well tolerated.
- Investigating treatment for apathy in Parkinson’s disease
- Assessing safety and tolerability of a potential new therapy
- Supporting research into symptoms that affect independence and quality of life
By covering both cognitive decline and behavioral symptoms, the site’s portfolio reflects a broad interest in complex neurological and psychiatric manifestations of brain disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Victoria Eugenia De La Cruz Roja Espanola
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy | Integrative Research Laboratories Sweden AB | Phase I | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 5 | Unknown | 2023-09-28 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.